Lantheus (NASDAQ:LNTH) Shares Gap Up to $67.39

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $67.39, but opened at $75.00. Lantheus shares last traded at $75.54, with a volume of 972,630 shares traded.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Truist Financial lifted their price objective on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday. Mizuho boosted their price target on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday. B. Riley increased their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. JMP Securities reissued a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $103.14.

Lantheus Stock Performance

The stock has a 50 day moving average of $62.67 and a two-hundred day moving average of $62.83. The stock has a market capitalization of $5.18 billion, a PE ratio of 11.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 5.45.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. Research analysts expect that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last three months, insiders sold 94,545 shares of company stock valued at $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. UMB Bank n.a. grew its holdings in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 247 shares during the last quarter. Tucker Asset Management LLC raised its stake in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the last quarter. Principal Securities Inc. purchased a new position in Lantheus in the 4th quarter valued at about $28,000. First Horizon Advisors Inc. grew its holdings in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 225 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in shares of Lantheus in the first quarter valued at approximately $34,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.